Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Cash & Equivalents: 2019-2024

Historic Cash & Equivalents for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to $55.5 million.

  • C4 Therapeutics' Cash & Equivalents fell 1.41% to $58.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.8 million, marking a year-over-year decrease of 1.41%. This contributed to the annual value of $55.5 million for FY2024, which is 56.16% down from last year.
  • As of FY2024, C4 Therapeutics' Cash & Equivalents stood at $55.5 million, which was down 56.16% from $126.6 million recorded in FY2023.
  • C4 Therapeutics' 5-year Cash & Equivalents high stood at $370.0 million for FY2020, and its period low was $29.8 million during FY2022.
  • In the last 3 years, C4 Therapeutics' Cash & Equivalents had a median value of $55.5 million in 2024 and averaged $70.6 million.
  • Per our database at Business Quant, C4 Therapeutics' Cash & Equivalents tumbled by 79.43% in 2021 and then soared by 325.46% in 2023.
  • C4 Therapeutics' Cash & Equivalents (Yearly) stood at $370.0 million in 2020, then tumbled by 79.43% to $76.1 million in 2021, then plummeted by 60.91% to $29.8 million in 2022, then surged by 325.46% to $126.6 million in 2023, then slumped by 56.16% to $55.5 million in 2024.